Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B

Chest

Volumn 113, Issue 3, 1998, Pages 723-731

  Herndon II, James E ^a   Green, Mark R ^b   Chahinian, A Phillippe ^c   Corson, Joseph M ^d   Suzuki, Yasunosuke ^c   Vogelzang, Nicholas J ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Mesothelioma; Prognostic factor; Survival

Indexed keywords

5,6 DIHYDROAZACITIDINE; ACICLOVIR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EDATREXATE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MITOMYCIN; PACLITAXEL; TRIMETREXATE;

ADULT; AGED; AGING; ARTICLE; ASBESTOSIS; CANCER SURVIVAL; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; THORAX PAIN;

EID: 0031887839     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.3.723     Document Type: Article

References (41)

1. Antman KH, Li FP, Pass HI, et al. Benign and malignant mesothelioma. In: DeVita VT Jr. Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippineott, 1993; 1489-1508
2. Chahinian AP. Malignant mesothelioma. In: Holland JF, Frei E, Bast RC:, et al. Eds. Cancer medicine. 3rd ed. Philadelphia: Lea & Febiger, 1993; 1337-54
3. Rusch VW. Diagnosis and treatment of pleural mesothelioma. Semin Surg Oncol 1990; 6:279-85
4. Ruffie PA. Pleural mesothelioma. Curr Opin Oncol 1991; 3:328-34
5. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14:1007-17
6. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubiein for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-65
7. Vogelzang NJ, Gontsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990; 27:239-42
8. Harmon D, Vogelzang N, Roboz J, et al. Dihydro-5-azacytidine in malignant mesothelioma using serum hyaluronic acid as a tumor marker: a phase II trial of the CALGB [abstract 1248]. Proc Am Soc Clin Oncol 1991; 10:A1248
9. Vogelzang NJ, Weissman LB, Herndon JE, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study. J Clin Oncol 1994; 12:1436-42
10. Samuels BL, Green VI, Harmon D, et al. Dihydro-5-azacytidine (DHAC) and cisplatin (DDP) in malignant mesothelioma [abstract 1470]. Proc Am Soc Clin Oncol 1992; 11:418
11. Samuels BL, Herndon J, Vogelzang NJ. Dihydro-5-azacytidine (DHAC) and cisplatin (DDP) in mesothelioma (CALGB 9031) [abstract 1371]. Proc Am Soc Clin Oncol 1994; 13:402
12. Belani CP, Herndon J, Vogelzang NJ, et al. Edatrexate for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB) [abstract 1087]. Proc Am Soc Clin Oncol 1994; 13:329
13. Belani C, Herndon JE, Vogelzang N, et al. Edatrexate with oral leucovorin rescue for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9131) [abstract 1068], Proc Am Soc Clin Oncol 1995; 14:352
14. Vogelzang NJ, Herndon J, Clamon G, et al. Paclitaxol (Taxol) for malignant mesothelioma (MM): a phase II study of the Cancer and Leukemia Group B (CALGB 9234) [abstract 1382]. Proc Am Soc Clin Oncol 1994; 13:405
15. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropnenmonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 1976; 31:15-24
16. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 1995; 108: 1122-28
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-70
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220
20. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69:239-41
21. Thernean TM, Grambsch PM, Fleming RT. Martingale based residuals for survival models. Biometrika 1990; 77: 147-60
22. Breiman L, Friedman JH, Olsen RA, et al. Classification and regression trees. Belmont, Calif: Wadsworth, 1984
23. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics 1992; 48:411-25
24. LeBlanc M, Crowley J. Survival trees by goodness of split. J Am Stat Assoc 1993; 88:456-67
25. Chailleux R, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988; 93:159-62
26. Tammilehto L, Maasilta P, Kostiainen S, et al. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of 65 patients. Respiration 1992; 59:129-35
27. Schildge J, Kaiser D, Henss H, et al. Prognostische faktoren beim diffusen malignen mesotheliom der pleura. Pneumologie 1989; 43:660-64
28. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-35
29. Ruffie R, Feld R, Minkin S, et al. Diffuse malignant mesothelionia of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7:1157-68
30. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1968-1985. J Clin Oncol 1988; 6:147-53
31. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988; 41:525-30
32. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982; 96:746-55
33. Boutin C, Rev F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecntive patients, part 2: prognosis and staging. Cancer 1993; 72:394-404
34. Viallat JR. Boutin C, Rev F, et al. Mesotheliome malin: etude des facteurs prognostiques sur une serie de 188 cas. Arch Anat Cytol Pathol 1993; 41:205-11
35. Fusco V, Ardizzoni A, Merlo F, et al. Malignant pleural mesothelioma: multivariate analysis of prognostic factors on 113 patients. Anticancer Res 1993; 13:683-90
36. Manzini VD, Brollo A, Franceschi S, et al. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993; 72:410-17
37. Calavrezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the pleura: a prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr 1988; 66:607-13
38. Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992; 8: 175-84
39. Van Gelder T, Damhuis RAM, Hoogsteden HC. Prognostic-factors and survival in malignant mesothelioma. Eur Respir J 1994; 7:1035-38
40. Chahinian AP, Pajak TF, Holland JF, et al. Adverse prognostic significance of thrombocytosis in patients with malignant mesothelioma. AACR Abstracts 1984; 25:161
41. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102:1-9